Experienced in Acute Myeloblastic Leukemia with Maturation

Dr. Brea C. Lipe

Hematology Oncology | Hematology | Oncology
University Of Rochester
601 Elmwood Ave, 
Rochester, NY 
Offers Telehealth
Experienced in Acute Myeloblastic Leukemia with Maturation
University Of Rochester
601 Elmwood Ave, 
Rochester, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brea Lipe is a Hematologist Oncology specialist and a Hematologist in Rochester, New York. Dr. Lipe is rated as an Experienced provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. Her top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Smoldering Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Strong Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY OF ROCHESTER
601 Elmwood Ave, Rochester, NY 14642

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 2
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drug: HPN217
Study Phase: Phase 1
A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Incomplete Freund's Adjuvant, Lenalidomide, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Study Phase: Phase 1
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: SEA-BCMA, Dexamethasone, Pomalidomide
Study Phase: Phase 1
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 2
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
Enrollment Status: Completed
Publish Date: June 18, 2021
Intervention Type: Drug
Study Drugs: Bortezomib, Granulocyte Colony-Stimulating Factor (G-CSF), Mozobil
Study Phase: Phase 2
View 6 Less Clinical Trials

46 Total Publications

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
Journal: Advances in therapy
Published: May 08, 2025
Similar Doctors
Jane Liesveld
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Jane Liesveld
Hematology | Oncology | Transplant Surgery
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Jane Liesveld
Hematology | Oncology | Transplant Surgery

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Liesveld is a Hematologist and an Oncologist in Rochester, New York. Dr. Liesveld is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Acute Myeloblastic Leukemia with Maturation
Dr. Jason H. Mendler
Hematology | Oncology | Transplant Surgery
Advanced in Acute Myeloblastic Leukemia with Maturation
Dr. Jason H. Mendler
Hematology | Oncology | Transplant Surgery

University Of Rochester

738 Library Rd, 
Rochester, NY 
 (0.4 miles away)
585-275-2638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Mendler is a Hematologist and an Oncologist in Rochester, New York. Dr. Mendler is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Bernard Poiesz
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Bernard Poiesz
Hematology | Oncology
Distinguished in Acute Myeloblastic Leukemia with Maturation
Dr. Bernard Poiesz
Hematology | Oncology

Auburn Community Hospital

17 Lansing St, 
Auburn, NY 
 (55.0 miles away)
315-255-7142
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bernard Poiesz is a Hematologist and an Oncologist in Auburn, New York. Dr. Poiesz is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia with Maturation. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Small Lymphocytic Lymphoma (SLL), Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lipe's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile